Signature Estate & Investment Advisors LLC lessened its stake in shares of Johnson & Johnson (NYSE:JNJ) by 16.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,566 shares of the company’s stock after selling 489 shares during the quarter. Signature Estate & Investment Advisors LLC’s holdings in Johnson & Johnson were worth $374,000 at the end of the most recent reporting period.
Several other institutional investors also recently modified their holdings of the company. Financial Advantage Inc. purchased a new stake in Johnson & Johnson in the third quarter valued at approximately $28,000. Kessler Investment Group LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $29,000. Exchange Traded Concepts LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter worth approximately $31,000. Eii Capital Management Inc. purchased a new position in shares of Johnson & Johnson during the third quarter worth approximately $39,000. Finally, Permanens Capital L.P. grew its position in shares of Johnson & Johnson by 33.3% during the third quarter. Permanens Capital L.P. now owns 400 shares of the company’s stock worth $52,000 after acquiring an additional 100 shares during the last quarter. Institutional investors and hedge funds own 67.91% of the company’s stock.
A number of research firms have weighed in on JNJ. Raymond James increased their price objective on Johnson & Johnson from $147.00 to $161.00 and gave the stock an “outperform” rating in a research report on Thursday, January 23rd. Barclays raised shares of Johnson & Johnson from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $140.00 to $173.00 in a report on Thursday, December 19th. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $158.00 target price on the stock in a report on Wednesday, December 18th. Cantor Fitzgerald reiterated a “buy” rating and set a $168.00 price target on shares of Johnson & Johnson in a research note on Thursday, January 23rd. Finally, Morgan Stanley raised shares of Johnson & Johnson from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $145.00 to $170.00 in a report on Tuesday, December 17th. Three research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Johnson & Johnson currently has an average rating of “Buy” and an average target price of $161.92.
Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, January 22nd. The company reported $1.88 EPS for the quarter, topping the consensus estimate of $1.87 by $0.01. Johnson & Johnson had a net margin of 22.18% and a return on equity of 39.30%. The company had revenue of $20.75 billion for the quarter, compared to analyst estimates of $20.83 billion. During the same period in the previous year, the firm earned $1.97 EPS. The business’s revenue was up 1.7% on a year-over-year basis. On average, equities research analysts predict that Johnson & Johnson will post 9.03 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 25th will be paid a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 2.56%. The ex-dividend date of this dividend is Monday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is 43.78%.
In other Johnson & Johnson news, COO Michael E. Sneed sold 58,128 shares of the company’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $149.39, for a total transaction of $8,683,741.92. Following the transaction, the chief operating officer now directly owns 107,511 shares in the company, valued at $16,061,068.29. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Hubert Joly bought 5,000 shares of the company’s stock in a transaction on Friday, December 13th. The stock was bought at an average cost of $141.28 per share, with a total value of $706,400.00. Following the completion of the acquisition, the director now owns 5,000 shares of the company’s stock, valued at approximately $706,400. The disclosure for this purchase can be found here. 0.23% of the stock is currently owned by insiders.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: Understanding the different types of bonds
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.